Cornell University College of Veterinary Medicine has published guidance on cannabidiol (CBD) and its use in veterinary medicine, addressing one of the questions practitioners field most often from companion-animal owners.

The guidance arrives as CBD products for pets occupy a gray zone: widely available to consumers, yet not approved as animal drugs by the FDA Center for Veterinary Medicine. That regulatory gap means veterinarians and pet owners are making decisions about CBD with an evidence base that is still developing, and Cornell's publication aims to clarify where the science stands.

What does the guidance cover?

The Cornell publication outlines what is currently known about CBD's uses and efficacy in animals. Its core message for clinicians and owners is that interest in cannabinoid products has outpaced the published evidence, and that claims on product labels do not always reflect what controlled studies have demonstrated.

For practitioners, the practical takeaway is straightforward: CBD is not a regulated drug in the animal health market, product quality and labeling vary widely across manufacturers, and any discussion with clients should separate what studies have shown from what marketing asserts.

Why does regulatory status matter at the exam table?

Because the FDA CVM has not approved CBD as a drug for animals, no CBD product carries agency-confirmed dosing, purity, or efficacy claims for veterinary use. That places the burden of product evaluation on the veterinarian and the owner.

The companion-animal implications are the clearest. Owners are already buying CBD for their dogs and cats, often without telling their veterinary team. Cornell's guidance gives clinicians a framework for those conversations: acknowledge the interest, explain the regulatory status, and counsel on the uncertainty that surrounds unapproved products.

Food-animal and public-health dimensions are more limited but worth noting. With no approval pathway exercised for CBD in food-producing species, residue and safety questions remain unresolved, which effectively rules out sanctioned use in cattle, swine, and poultry under current rules.

What should veterinarians take from it?

The Cornell publication functions less as a endorsement of CBD than as a primer on how to evaluate it. It walks through the compound's proposed uses, the state of efficacy evidence behind them, and the constraints that the current regulatory framework places on veterinary recommendation.

For a profession navigating client demand that runs ahead of the data, that framing matters. Clinicians who can state clearly what is known, what is not, and why approval status matters are better positioned to counsel clients than those who either dismiss or accept CBD categorically.

Cornell's guidance signals that veterinary colleges now treat cannabinoid questions as core client-communication territory rather than a fringe topic, and further peer-reviewed work will determine whether CBD earns a place in the formulary.